PlumX Metrics
Embed PlumX Metrics

Combined pathologies in FTLD-TDP types A and C

Journal of Neuropathology and Experimental Neurology, ISSN: 1554-6578, Vol: 77, Issue: 5, Page: 405-412
2018
  • 9
    Citations
  • 0
    Usage
  • 49
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Combined Pathologies in FTLD-TDP Types A and C.

J Neuropathol Exp Neurol. 2018 Mar 23; Authors: Gefen T, Ahmadian SS, Mao Q, Kim G, Seckin M, Bonakdarpour B, Ramos EM, Coppola G, Rademakers R, Rogalski E, Rademaker A, Weintraub S, Mesulam MM, Geula C, Bigio EH PubMed: 29584904 Submit Comment

Article Description

This study investigated the presence of combined pathologies in a large cohort of autopsies that show a primary pathologic diagnosis of phosphorylated 43-kDa TAR DNA-binding protein (FTLD-TDP), the majority of which portrayed clinical phenotypes consistent with primary progressive aphasia or behavioral variant frontotemporal dementia (bvFTD). Thirty-eight cases with FTLD-TDP (30 type-A and 8 type-C) were identified to determine characteristic differences between cases with and without combined pathologies. Findings indicated that combined pathologies co-occur with FTLD-TDP type-A at a high frequency (50%)-greater than when compared to FTLDTDP type-C cases (12.5%). Those with FTLD-TDP type-A and combined pathologies showed significantly longer lifespans (p < 0.05), and longer disease durations (p < 0.05), than those with only FTLDTDP type-A. Cases with FTLD-TDP type-A and known genetic mutations tended not to show combined pathology. Those with the GRN mutation and FTLD-TDP type-A showed a significantly younger age of onset (p < 0.05) and younger age at death (p < 0.01) compared to noncarriers. In 1 bvFTD case, we highlight the rare presence of "triple" FTLD-TDP type-A, FTLD-tau, and Alzheimer pathology. The ante- and post-mortem features associated with combined pathologies in FTLD-related disorders are of useful consideration in the stratification of patients to drug trials, and in the development of therapeutic targets for FTLD.

Bibliographic Details

Gefen, Tamar; Ahmadian, Saman S; Mao, Qinwen; Kim, Garam; Seckin, Mustafa; Bonakdarpour, Borna; Ramos, Eliana Marisa; Coppola, Giovanni; Rademakers, Rosa; Rogalski, Emily; Rademaker, Alfred; Weintraub, Sandra; Mesulam, M-Marsel; Geula, Changiz; Bigio, Eileen H

Oxford University Press (OUP)

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know